LYEL Lyell Immunopharma, Inc. stock chart & analysis
Conviction 9HealthcareScan · Fri, Nov 6, 2026Lyell Immunopharma, Inc. (LYEL) closed at $14.86 (-0.93%) on Nov 6, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 74, RS Rating 60, -67.0% from its 52-week high, -51.8% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
LYEL technical analysis
Trend
LYEL's moving averages are mixed — no clean uptrend or downtrend. It closed 36.6% above the 50-day ($10.86) and 10.6% below the 200-day ($16.60). ADX(14) at 38 points to a strong, established trend. It meets 3 of 8 trend-template criteria.
Momentum
RSI(14) is 74, in overbought territory. The MACD histogram is positive. Its RS Rating of 60 puts its weighted 12-month performance ahead of about 60% of the US market.
Volume and volatility
Volume on the latest session ran 2.1× its 20-day average. It trades about $2.9M a day on average. ATR(14) is $1.23, 8.3% of price — its typical daily range. Chaikin Money Flow (0.10) shows accumulation.
Key levels
The chart pattern's support is $7.70 and its resistance $14.18. The 52-week range is $7.20 to $45.00; price is 67.0% below the high and 106.2% above the low. The VWAP anchored at the 52-week high is $16.64, above price.
Performance
LYEL returned +34.4% (1 week), +68.8% (1 month), +3.5% (3 months), -23.3% (6 months), -10.3% (1 year), -51.8% (year to date).
About Lyell Immunopharma, Inc.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Pharmaceutical Preparations · Listed 2021 · 161 employees
Recent news
- Lyell Immunopharma: Q3 Earnings SnapshotYahoo Finance · Wed, Nov 4, 2026
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026Yahoo Finance · Wed, Nov 4, 2026
- Why Is Lyell Immunopharma Stock (LYEL) Up over 43% Today?TipRanks · Wed, Nov 4, 2026
- Why Did Lyell Immunopharma (NASDAQ:LYEL) Soar 42.5% Within a Single Session?kalkine.ca · Wed, Nov 4, 2026
- What Is Lifting Lyell Immunopharma (NASDAQ:LYEL) Shares 32.59% Higher Following an USD 80 Million Placement?kalkine.ca · Wed, Nov 4, 2026
- Lyell Immunopharma raises $80 million in private placement By Investing.comInvesting.com Canada · Wed, Nov 4, 2026
- Form 8K Lyell Immunopharma Inc For: 4 November By Investing.comInvesting.com UK · Wed, Nov 4, 2026
- Lyell Immunopharma to sell 7.43M shares at $10.77 in private placementTipRanks · Wed, Nov 4, 2026
- Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA SubmissionYahoo Finance · Wed, Nov 4, 2026
- Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell LymphomaYahoo Finance · Wed, Nov 4, 2026
Insider activity
SEC Form 4 transactions in LYEL · open-market 2 buys · 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
ARCH Venture Partners IX, LLC 10% owner · Common Stock · 2026-11-04 | Buy | 2.32M | $25M | 2026-11-04 | 2026-11-05 |
ARCH Venture Fund XIII, L.P. 10% owner · Common Stock · 2026-11-04 | Buy | 2.32M | $25M | 2026-11-04 | 2026-11-05 |
Hill Stephen J. Chief Operating Officer · Common Stock · 2026-08-21 | Sell | 989 | $15K | 2026-08-21 | 2026-08-25 |
Lee Gary K. Chief Scientific Officer · Common Stock · 2026-08-21 | Sell | 1.46K | $23K | 2026-08-21 | 2026-08-25 |
Seely Lynn President and CEO · Common Stock · 2026-08-21 | Sell | 9.59K | $149K | 2026-08-21 | 2026-08-25 |
Bulis Veronica Sanchez VP, Corporate Controller · Common Stock · 2026-08-10 | Sell | 621 | $9K | 2026-08-10 | 2026-08-11 |
Hill Stephen J. Chief Operating Officer · Common Stock · 2026-08-10 | Sell | 89 | $1K | 2026-08-10 | 2026-08-11 |
Lee Gary K. Chief Scientific Officer · Common Stock · 2026-08-10 | Sell | 131 | $2K | 2026-08-10 | 2026-08-11 |
Seely Lynn President and CEO · Common Stock · 2026-08-10 | Sell | 390 | $6K | 2026-08-10 | 2026-08-11 |
Innovative Cellular Therapeutics Holdings Ltd 10% owner · Common Stock · 2026-07-27 | Dispose | 38.5K | — | 2026-07-27 | 2026-07-27 |
SEC filings
EDGAR filings in LYEL · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.